ERBB2 and carcinoma: We were able to demonstrate that the antibodies raised to the short glycosylated Her2 peptide, Lac-Her2(282–294), were capable of inhibiting the growth of Her2 expressing SKBR3 carcinoma cells, and this growth inhibition effect was superior to what was observed with its non-glycosylated counterpart.